WVE · Insider Trading
Wave Life Sciences Ltd. Ordinary Shares
Every open-market purchase and sale reported by WVE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | Heidi L Wagner | Director | A | +10,700 | — |
| 2026-10-07 | Christian O Henry | Director | A | +10,700 | — |
| 2026-10-07 | Adrian Rawcliffe | Director | A | +10,700 | — |
| 2026-10-07 | Mark Corrigan | Director | A | +10,700 | — |
| 2026-10-07 | Ken Takanashi | Director | A | +10,700 | — |
| 2026-10-07 | Gregory L. Verdine | Director | A | +10,700 | — |
| 2026-10-07 | RA CAPITAL MANAGEMENT, L.P. | Director | A | +42,800 | — |
| 2026-10-07 | Aik Na Tan | Director | A | +10,700 | — |
| 2026-08-13 | Aik Na Tan | Director | Sell | −432 | −$2.60K |
| 2026-08-13 | Heidi L Wagner | Director | MIXED | — | −$280 |
| 2026-08-13 | Adrian Rawcliffe | Director | Sell | −12,700 | −$67.18K |
| 2026-08-13 | Ken Takanashi | Director | Sell | −3,864 | −$23.22K |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | +35,089,984 | +$218.50M |
| 2026-03-26 | Ken Takanashi | Director | C | +3,901,348 | — |
| 2026-02-27 | Chris Francis | See Remarks | MIXED | — | −$357.67K |
| 2026-02-11 | Kyle Moran | Chief Financial Officer | MIXED | +42,037 | −$48.26K |
| 2026-02-11 | Paul Bolno | President and CEO | MIXED | +154,520 | −$140.96K |
| 2026-02-11 | Chris Francis | See Remarks | MIXED | +36,867 | −$25.33K |
| 2026-02-11 | Chandra Vargeese | See Remarks | MIXED | +42,397 | −$43.42K |
| 2026-01-06 | Chris Francis | See Remarks | MIXED | — | −$120.82K |
| 2025-12-15 | GSK plc | 10%+ Owner | Buy | +1,470,000 | +$27.93M |
| 2025-12-10 | Gregory L. Verdine | Director | Sell | −20,000 | −$269.46K |
| 2025-12-10 | Mark Corrigan | Director | Sell | −16,115 | −$217.30K |
| 2025-12-10 | Heidi L Wagner | Director | MIXED | −7,000 | −$147.21K |
| 2025-12-10 | Adrian Rawcliffe | Director | MIXED | — | −$379.26K |
| 2025-12-10 | Kyle Moran | Chief Financial Officer | MIXED | +35,964 | −$2.56M |
| 2025-12-10 | Chris Francis | See Remarks | MIXED | — | −$4.32M |
| 2025-12-10 | Aik Na Tan | Director | MIXED | +6,012 | −$977.14K |
| 2025-12-10 | Christian O Henry | Director | MIXED | −6,445 | −$928.53K |
| 2025-11-14 | Adrian Rawcliffe | Director | Sell | −16,115 | −$109.42K |
| 2025-11-14 | RA Capital Healthcare Fund LP | Director | Buy | +4,000 | +$26.75K |
| 2025-08-26 | Paul Bolno | President and CEO | Sell | −217,351 | −$2.19M |
| 2025-08-26 | Gregory L. Verdine | Director | Sell | −10,000 | −$100.00K |
| 2025-08-19 | Aik Na Tan | Director | MIXED | — | −$2.52K |
| 2025-08-13 | Ken Takanashi | Director | A | +12,700 | — |
| 2025-08-13 | Aik Na Tan | Director | A | +25,400 | — |
| 2025-08-13 | Heidi L Wagner | Director | A | +12,700 | — |
| 2025-08-13 | Adrian Rawcliffe | Director | A | +12,700 | — |
| 2025-08-13 | Mark Corrigan | Director | A | +12,700 | — |
| 2025-08-13 | Gregory L. Verdine | Director | A | +12,700 | — |
| 2025-08-13 | Christian O Henry | Director | MIXED | +3,030 | −$85.19K |
| 2025-08-13 | Rajeev M. Shah | Director | A | +50,800 | — |
| 2025-08-07 | Ken Takanashi | Director | Sell | −4,872 | −$42.63K |
| 2025-08-07 | Aik Na Tan | Director | Sell | −1,127 | −$9.86K |
| 2025-06-13 | Gregory L. Verdine | Director | Sell | −30,000 | −$208.50K |
| 2025-03-21 | Christian O Henry | Director | MIXED | — | −$6.71K |
| 2025-03-07 | Paul Bolno | President and CEO | MIXED | — | −$1.20M |
| 2025-03-07 | Gregory L. Verdine | Director | M | +266,402 | +$660.68K |
| 2025-03-05 | Chandra Vargeese | See Remarks | M | +91,754 | +$227.55K |
| 2025-02-06 | Chandra Vargeese | See Remarks | A | +37,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| GSK plc | 10%+ Owner | 18,245,691 | $58.57M |
| RA Capital Healthcare Fund LP | Director | 18,203,009 | $58.43M |
| Ken Takanashi | Director | 9,637,187 | $30.94M |
| Chandra Vargeese | See Remarks | 411,474 | $1.32M |
| Gregory L. Verdine | Director | 275,917 | $885.69K |
| Paul Bolno | President and CEO | 275,520 | $884.42K |
| Kyle Moran | Chief Financial Officer | 134,385 | $431.38K |
| Chris Francis | See Remarks | 77,161 | $247.69K |
| Heidi L Wagner | Director | 55,630 | $178.57K |
| Mark Corrigan | Director | 39,515 | $126.84K |
| RA CAPITAL MANAGEMENT, L.P. | Director | 39,515 | $126.84K |
| Aik Na Tan | Director | 35,668 | $114.49K |
| Rajeev M. Shah | Director | 28,815 | $92.50K |
| Christian O Henry | Director | 23,400 | $75.11K |
| Adrian Rawcliffe | Director | 10,700 | $34.35K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the WVE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.